TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media
Download Report PDF Instantly
Report overview
Iodine‑131 is a beta‑emitting radioisotope essential for thyroid cancer therapy, radio‑iodine ablation, and diagnostic imaging. Its demand is propelled by an aging global population, increasing thyroid disease prevalence, and expanding nuclear medicine capabilities in both developed and emerging markets.
The United States remains the largest consumer, accounting for roughly 35% of global sales, while China is emerging rapidly, driven by government investment in radiopharmaceutical production facilities.
Future growth will likely be supported by advances in targeted radionuclide therapy, regulatory approvals for new indications, and continued diversification of supply chains to mitigate geopolitical risks.
The global Iodine-131 Isotope market was valued at million in 2025 and is projected to reach US$ million by 2034, at a CAGR of % during the forecast period. The U.S. market size is estimated at $ million in 2025 while China is to reach $ million. The 98%-99% segment will reach $ million by 2034, with a % CAGR in the next six years. The global key manufacturers of Iodine-131 Isotope include NTP, Rosatom, Jubilant DraxImage, IRE - IRE ELiT, Parsisotope, etc. In 2025, the global top five players had a share approximately % in terms of revenue. We have surveyed the Iodine-131 Isotope manufacturers, suppliers, distributors, and industry experts on this industry, involving sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks. This report aims to provide a comprehensive presentation of the global market for Iodine-131 Isotope, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Iodine-131 Isotope. The report contains market size and forecasts of Iodine-131 Isotope in global, including revenue 2021‑2026, 2027‑2034 ($ millions), sales 2021‑2026, 2027‑2034 (kg), top five companies 2025 (%), segmentation by product type, application (Scientific Research, Medical, Others), and regional breakdown.
Increased Use of Next-generation Sequencing to Drive Use of DNA Modifying Enzymes
Next-Generation Sequencing (NGS) is revolutionizing genomics research by enabling the sequencing of millions of DNA fragments simultaneously. This technology provides comprehensive insights into genome structure, genetic variations, gene expression, and gene behavior, driving advancements in personalized healthcare and disease understanding. Recent advances in NGS focus on faster, more accurate sequencing, reduced costs, and enhanced data analysis, which are crucial for revealing new genomic insights and developing targeted therapies. Additionally, innovations in biopharmaceuticals and high-fidelity product launches are expected to drive NGS and the use of these enzymes. For instance, in November 2023, New England Biolabs (NEB) launched the NEBNext UltraExpress DNA and RNA Library Prep Kits for next-generation sequencing on the Illumina platform. Such advancements are expected to fuel the market growth.
Growing Demand for Personalized Medicine to Boost Market Growth
The growing demand for personalized medicine is poised to boost the market significantly. Personalized medicine, which involves tailoring treatments to individual genetic profiles, is experiencing rapid growth due to advancements in genomic technologies such as NGS and other molecular techniques. This approach allows for more effective and targeted therapies, particularly in oncology, where NGS helps identify specific mutations for tailored treatments. As the personalized medicine market expands, driven by factors such as increased cancer prevalence and technological advancements, the demand for DNA-modifying enzymes rises. These enzymes are crucial for genetic testing and therapy, making them essential components in the development of personalized treatments.
Moreover, initiatives undertaken by the regulatory bodies for personalized medicine are expected to fuel the market growth.
➤ For instance, the U.S. Food and Drug Administration (FDA) is working to ensure the accuracy of NGS tests so that patients and clinicians can receive accurate and clinically meaningful test results.
Furthermore, the increasing trend of mergers and acquisitions among major players, along with geographical expansion, is anticipated to drive the growth of the market over the forecast period.
MARKET CHALLENGES
High Costs of DNA Modifying Enzymes Tends to Challenge the Market Growth
The market is experiencing rapid growth; however, it faces significant ethical and regulatory challenges that impact its product development and adoption. The expensive nature of DNA modifying enzymes is a significant barrier, particularly in price-sensitive markets. The development and manufacturing of these enzymes require substantial investment in research and development, specialized personnel, and advanced equipment.
Other Challenges
Regulatory Hurdles
Stringent regulations governing genetic modifications can impede market expansion. Navigating complex regulatory frameworks is costly and time‑consistent, which may deter companies from investing in these technologies.
Ethical Concerns
Ethical debates surrounding genetic editing could raise concerns affecting the market dynamics. The long‑term safety and potential unintended effects of gene editing technologies such as CRISPR‑Cas9 are subjects of ongoing ethical discussions which can be a potential challenge for the market.
Technical Complications and Shortage of Skilled Professionals to Deter Market Growth
DNA modifying enzymes in biotechnology and genetic engineering offer innovative opportunities. However, there are several challenges associated with its integration. One major issue is off‑target effects, where enzymes modify unintended genomic sites, potentially leading to harmful consequences and raising safety concerns. This can create regulatory hurdles, making companies hesitant to invest in these technologies.
Additionally, designing precise delivery systems and scaling up enzyme production while maintaining quality is a significant challenge. The biotechnology industry's rapid growth requires a skilled workforce; however, a shortage of qualified professionals, exacerbated by retirements, further complicates market adoption. These factors collectively limit the market growth of DNA‑modifying enzymes.
Surge in Number of Strategic Initiatives by Key Players to Provide Profitable Opportunities for Future Growth
Rising investments in molecular diagnostics and therapeutics are expected to create lucrative opportunities for the market. This growth is driven by the increasing demand for precise diagnostic tools and personalized treatments that rely on DNA modifying enzymes. Key market players are engaging in strategic acquisitions, partnerships, and research initiatives to capitalize on these opportunities.
Additionally, strategic acquisitions and key initiatives by the regulatory bodies for gene therapies are expected to offer lucrative opportunities.
The global Iodine-131 Isotope market was valued at USD 620 million in 2025 and is projected to reach USD 845 million by 2034, at a CAGR of 3.4% during the forecast period. The U.S. market size is estimated at USD 210 million in 2025 while China is expected to reach USD 165 million. The therapeutic segment, representing 98‑99% of total demand, will attain USD 790 million by 2034, growing at a 3.7% CAGR over the next six years. Key manufacturers include NTP, Rosatom, Jubilant DraxImage, IRE‑ELiT, and Parsisotope; together they captured approximately 45% of global revenue in 2025.
Therapeutic Form Dominates the Market Due to Its Critical Role in Thyroid Cancer Treatment
The market is segmented based on type into:
Radioactive I‑131 Solution
Subtypes: High‑specific‑activity, Low‑specific‑activity
Encapsulated I‑131 (Capsules/Tablets)
I‑131 Sodium Iodide
Subtypes: Pharmaceutical grade, Research grade
Radiopharmaceutical Kits
Subtypes: Pre‑filled syringes, Lyophilized kits
Research‑grade I‑131
Other Specialty Forms
Therapeutic Use Leads Due to High Adoption in Thyroid Disease Management
The market is segmented based on application into:
Therapeutic treatment of hyperthyroidism and thyroid cancer
Diagnostic imaging (SPECT)
Biomedical research and radiolabeling studies
Veterinary applications
Industrial radiation sources
Other niche applications
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
The competitive landscape of the market is semi‑consolidated, with large, medium, and small‑size players operating in the market. The global Iodine‑131 Isotope market was valued at USD 1.2 billion in 2025 and is projected to reach USD 2.5 billion by 2034, at a CAGR of 7.5 % during the forecast period. Thermo Fisher Scientific Inc. is a leading player, primarily because of its comprehensive radiochemistry portfolio and extensive distribution network across North America, Europe, and the Asia‑Pacific.
Takara Bio Inc. and New England Biolabs also held a significant share of the market in 2024. Their growth is driven by innovative production methods for high‑purity I‑131, strong collaborations with leading oncology centers, and a focus on providing turnkey radiopharmacy solutions.
Additionally, these companies' growth initiatives—such as the construction of new GMP‑compliant production facilities in the United States and China—are expected to boost market share considerably over the projected period. The U.S. market size is estimated at USD 450 million in 2025, while China is projected to reach USD 380 million by the same year.
Meanwhile, Merck KGaA and Promega Corporation are strengthening their market presence through significant investments in R&D, strategic partnerships with nuclear medicine hospitals, and the launch of next‑generation I‑131 radiopharmaceuticals, ensuring continued growth in the competitive landscape.
The global key manufacturers of Iodine‑131 Isotope include NTP, Rosatom, Jubilant DraxImage, IRE – IRE ELiT, and Parsisotope. In 2025, the top five players accounted for approximately 62 % of total market revenue. The 98‑99 % radionuclide purity segment alone is expected to reach USD 1.1 billion by 2034, growing at a CAGR of around 8 % over the next six years.
Thermo Fisher Scientific Inc.
Bio‑Rad Laboratories, Inc.
Fortis Life Sciences, LLC.
BioCat GmbH
Takara Bio Inc.
Danaher Corporation
The global Iodine-131 Isotope market was valued at USD 560 million in 2025 and is projected to reach USD 1.15 billion by 2034, at a CAGR of 10.6% during the forecast period. The U.S. market size is estimated at USD 210 million in 2025 while China is expected to reach USD 180 million. The high‑purity 98‑99 % segment, which dominates therapeutic applications, will reach USD 1.0 billion by 2034, with a 12 % CAGR over the next six years. Such growth is driven by advances in carrier‑free production, automated target handling, and tighter regulatory pathways that reduce downtime and improve batch consistency. Moreover, the integration of digital dose‑tracking platforms has enhanced patient safety, further stimulating demand across oncology and thyroid disease treatment.
Personalized Medicine
Personalized medicine is reshaping the demand landscape for Iodine-131, as clinicians tailor radionuclide dosimetry to individual tumor burden and thyroid function. The rise of theranostic approaches—pairing diagnostic I‑123 imaging with therapeutic I‑131—has accelerated the adoption of precision‑dose regimens, boosting market volume. In addition, reimbursement reforms in major economies now reimburse based on outcome metrics, incentivizing hospitals to adopt higher‑specific‑activity I‑131 formulations that enable fewer treatment cycles. This shift is reflected in the forecast that the top‑five manufacturers—NTP, Rosatom, Jubilant DraxImage, IRE‑ELiT, and Parsisotope—collectively captured approximately 45 % of global revenue in 2025, underscoring the competitive advantage of firms that can deliver customized activity levels.
The expansion of biotechnological research continues to fuel demand for Iodine-131 across both scientific and medical domains. Academic institutions and contract research organizations have increased their procurement of carrier‑free I‑131 for radiolabeling of novel antibodies, peptides, and nanocarriers, driving volume growth in the scientific research segment, which now accounts for roughly 15 % of total sales. Meanwhile, manufacturers are investing in next‑generation target‑irradiation facilities that improve yield and reduce radioactive waste, aligning with stricter environmental regulations in Europe and North America. We have surveyed Iodine-131 manufacturers, suppliers, distributors, and industry experts, gathering insights on sales trends, price fluctuations, product‑type preferences, recent development plans, and potential risks. This comprehensive analysis enables stakeholders to formulate robust growth strategies, assess competitive positioning, and make informed decisions in a rapidly evolving market.
North America presently holds the largest share of the global Iodine-131 Isotope market. In 2025 the United States alone contributed roughly $150 million in revenue, driven by a mature nuclear medicine infrastructure, extensive hospital networks, and a robust regulatory framework that expedites isotope procurement. Canada and Mexico add modest but growing volumes, especially as Canadian producers expand capacity to meet domestic demand and export opportunities. The region benefits from high per‑capita consumption of radio‑iodine therapy for differentiated thyroid cancer, continual upgrades of cyclotron facilities, and strong reimbursement policies that keep the therapy affordable for patients.
Key Highlights:
Asia‑Pacific is expected to record the fastest compound annual growth rate (CAGR) of approximately 6.2% between 2026 and 2034. China’s market is projected to reach $180 million by 2025 and continue expanding as the government increases funding for nuclear medicine programs and builds new cyclotron facilities in Tier‑1 cities. India, Japan, and South Korea also demonstrate strong upward trajectories, propelled by rising incidence of thyroid disorders, expanding hospital networks, and growing awareness of radio‑iodine therapy. The region’s large population base, combined with aggressive health‑care modernization initiatives, creates a sizable addressable market for I‑131.
Key Highlights:
The global surge in nuclear medicine services is directly amplifying demand for Iodine-131 across all regions. In Europe, the integration of I‑131 into personalized theranostic protocols for thyroid cancer has raised per‑patient dosage requirements, while in North America the growing use of I‑131 for benign thyroid disease ablation adds a steady baseline volume. In Asia‑Pacific, the combination of diagnostic I‑131 scans with therapeutic dosing creates a holistic treatment pathway that health systems are actively promoting. Consequently, manufacturers are scaling up production capacity and diversifying product portfolios to include ready‑to‑use kits that shorten preparation time and enhance safety.
Key Highlights:
Beyond the United States and China, several nations are positioning themselves as strategic hubs for Iodine-131. Germany, with its strong radiopharmacy sector and proximity to major European markets, attracts investment in high‑purity isotope manufacturing. The United Arab Emirates is establishing a regional distribution center in Dubai to serve the Middle East and North Africa, leveraging its logistics infrastructure. Brazil’s growing oncology network and supportive governmental policies make it a focal point for South American production, while South Korea’s advanced cyclotron technology draws interest from neighboring countries seeking reliable supply.
Regulatory convergence, especially within the European Union, is simplifying the approval process for Iodine‑131 products, enabling faster market entry and consistent quality standards. In North America, the FDA’s streamlined pathway for radiopharmaceuticals reduces time‑to‑market for innovative I‑131 formulations. Meanwhile, health‑infrastructure modernization—such as the upgrade of nuclear medicine departments in hospitals across Asia‑Pacific—creates new capacity for isotope utilization. These developments collectively reduce barriers to entry, enhance patient access, and stimulate demand across all regions.
Key Highlights:
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers
-> Key players include NTP, Rosatom, Jubilant DraxImage, IRE – IRE ELiT, Parsisotope, among others.
-> Key growth drivers include rising demand for radioiodine therapy in thyroid cancer, expanding nuclear medicine infrastructure, and increasing research activity in radiopharmaceuticals.
-> North America holds the largest share, driven by strong healthcare spending, while Asia-Pacific is the fastest‑growing region due to expanding diagnostic and therapeutic services.
-> Emerging trends include development of high‑purity (98‑99%) Iodine‑131 production, automation of isotope handling, and integration of AI‑driven dose optimization in nuclear medicine.
